Crizotinib (Xalkori)
Targeted Therapy · Approved since 2011
Description
Crizotinib is an oral tyrosine kinase inhibitor primarily approved for ALK-positive non-small cell lung cancer that has been explored in colorectal cancer through precision medicine approaches. In CRC, crizotinib is used off-label for tumors harboring specific genetic alterations, particularly ALK rearrangements or ROS1 fusions, which occur in a small subset of patients. The drug represents a targeted approach for patients whose tumors demonstrate these rare but actionable molecular alterations identified through comprehensive genomic profiling.
Mechanism of Action
Crizotinib selectively inhibits multiple receptor tyrosine kinases, including ALK (anaplastic lymphoma kinase), ROS1, and MET kinases. By blocking these aberrant signaling pathways, the drug disrupts tumor cell proliferation and survival mechanisms that drive cancer growth in genetically defined patient populations.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Xalkori |
| Category | Targeted Therapy |
 Status | Off-label |
 EMA Status | EMA Approved |
 Spain Access | Hospital use off-label in CRC |
| Administration | Oral |
| Year Approved | 2011 |
| Clinical Trials | 4 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.